Lipoproteins, E.g., Egg Yolk Proteins, Cylomicrons, Etc. Patents (Class 530/359)
  • Patent number: 10087235
    Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nrn to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-f preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: October 2, 2018
    Assignee: CSL LIMITED
    Inventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
  • Patent number: 9937229
    Abstract: The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: April 10, 2018
    Assignee: CSL Behring AG
    Inventor: Nathan Brinkman
  • Patent number: 9494606
    Abstract: Some aspects of this disclosure provide methods and reagents for the detection of apolipoproteins in a sample, for example, a sample obtained from a human subject. Some aspects of this disclosure provide protocols and reagents for the quantification of lipoproteins and lipoprotein particle populations comprising specific combinations of non-integral apolipoproteins and integral apolipoproteins, which is useful, inter alia, for the detection of diseases such as cardiovascular disease as well as an assessment of the risk of an individual to develop a disease.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: November 15, 2016
    Assignee: President and Fellows of Harvard College
    Inventors: Frank M. Sacks, Jeremy D. Furtado
  • Patent number: 9243056
    Abstract: A process is provided for the preparation of an immunoglobulin composition from a plasma fraction having immunoglobulins, and antibody preparations prepared utilizing the process.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: January 26, 2016
    Assignee: BIOTEST AG
    Inventors: Wolfgang Moeller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Herbert Dichtelmueller, Eckhard Flechsig
  • Patent number: 9125943
    Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: September 8, 2015
    Assignee: CSL LIMITED
    Inventors: Yvonne Vucica, Gary Lee Warren
  • Publication number: 20150148410
    Abstract: An isolated peptidic fragment of apolipoprotein E comprises at least 3 contiguous amino acids, Including glycosylated threonine 194, threonine 289, serine 94, or serine 76 of SEQ ID NO.: 1, or any combination of those. An antibody capable of binding to the isolated peptidic fragment. A method of detecting a naturally-occurring circulating atherogenic low-density lipoprotein in a plasma sample from an individual, comprising qualitatively and/or quantitatively detecting in a low-density lipoprotein that binds to the antibody. A method of assessing an individual's risk of ischemic heart disease and/or atherosclerosis comprises quantifying in a plasma sample from the individual an amount of apolipoprotein E comprising glycosylated threonine 194, threonine 289, serine 94 or serine 76 of SEQ ID NO.: 1, or any combination of those.
    Type: Application
    Filed: September 10, 2012
    Publication date: May 28, 2015
    Applicant: Texas Heart Institute
    Inventors: Chu-Huang Chen, Liang-Yin Ke
  • Publication number: 20150148259
    Abstract: Novel phenyl-glyoxal based anti-citrulline probes and methods of synthesis are provided. Methods of use, such as, the development of methods for monitoring substrate citrullination over time; for identifying citrullinated proteins from cells are described.
    Type: Application
    Filed: June 4, 2013
    Publication date: May 28, 2015
    Inventors: Paul R. Thompson, Kevin L. Bicker, Venkataraman Subramanian
  • Publication number: 20150132859
    Abstract: The invention relates to a method for detecting antibodies against the TpN17 antigen of Treponema pallidum in an isolated sample wherein a peptide sequence of Vibrio cholerae lipoprotein 15 (VcLp15) or a partial sequence thereof is used as a reagent for reduction of interference, i.e. for minimizing false positive results. In addition the invention relates to fusion polypeptides comprising a VcLp15 peptide sequence and a chaperone, to their use as an additive in an immunoassay for said reduction of interferences and for minimizing false positive results and to a reagent kit for detecting antibodies against Treponema pallidum antigens in an isolated sample comprising a TpN17 antigen and said VcLp15-chaperone fusion polypeptide.
    Type: Application
    Filed: July 18, 2014
    Publication date: May 14, 2015
    Inventors: Elke Faatz, Peter Schaarschmidt, Urban Schmitt, Christian Scholz
  • Publication number: 20150105538
    Abstract: Provided herein are methods and systems for assembling, solubilizing and/or purifying a membrane associated protein in a nanolipoprotein particle, which comprise a temperature transition cycle performed in presence of a detergent, wherein during the temperature transition cycle the nanolipoprotein components are brought to a temperature above and below the gel to liquid crystalling transition temperature of the membrane forming lipid of the nanolipoprotein particle.
    Type: Application
    Filed: November 7, 2014
    Publication date: April 16, 2015
    Inventors: Brett A. CHROMY, Paul HENDERSON, Paul D. HOEPRICH, JR.
  • Patent number: 8999320
    Abstract: Methods for rapidly obtaining a nanoscale apolipoprotein bound phospholipid bilayer (NABB) associated with at least one membrane protein are provided. Also disclosed are methods for rapidly obtaining a NABB not associated with membrane proteins. Immunogenic compositions comprising NABBs with native conformational epitopes are also provided along with their methods of use.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: April 7, 2015
    Assignee: The Rockefeller University
    Inventors: Thomas P. Sakmar, Thomas Huber, Sourabh Banerjee
  • Patent number: 8986700
    Abstract: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: March 24, 2015
    Assignee: The Council of the Queensland Institute of Medical Research
    Inventors: David Jackson, Weiguang Zeng
  • Publication number: 20150072937
    Abstract: Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene.
    Type: Application
    Filed: March 17, 2014
    Publication date: March 12, 2015
    Applicant: Children's Medical Center Corporation
    Inventors: Yi Zheng, David A. Williams
  • Patent number: 8962802
    Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A.sub.1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: February 24, 2015
    Assignee: CSL Behring GmbH
    Inventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
  • Publication number: 20150017148
    Abstract: In certain embodiments compositions are provided that comprise a pentapeptide comprising the formula: C1-X2-X3-X4-C5 where C1 and C5 are independently selected cysteines or cysteine analogues, or other amino acids with sidechains suitable for cyclization, where the cysteines or cysteine analogs are attached to each other by a linkage that does not comprise X2, X3, and X4; where X2, X3, and X4 are independently selected amino acids; and the peptide, when administered to a cell alters APP signaling and/or switches APP processing from aberrant to normal. The compositions mitigate amyloid plaque formation.
    Type: Application
    Filed: November 27, 2012
    Publication date: January 15, 2015
    Inventors: Varghese John, Clare Peters-Libeu, Dale E. Bredesen
  • Publication number: 20150011459
    Abstract: Herein is reported a shortened tetranectin-apolipoprotein A-I fusion protein and a lipid particle comprising the shortened tetranectin-apolipoprotein A-I fusion protein as well as uses thereof.
    Type: Application
    Filed: June 25, 2014
    Publication date: January 8, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Martin Bader, Roberto Falkenstein, Christian Schantz
  • Publication number: 20140378376
    Abstract: An apolipoprotein formulation is provided at a fixed dosage that is efficacious in the prophylactic and/or therapeutic treatment of diseases or conditions including, but not limited to cardiovascular disease, acute coronary syndrome, atherosclerosis, unstable angina pectoris, and myocardial infarction. More particularly, the fixed dosage apolipoprotein formulation displays relatively reduced inter-patient variability compared to weight-adjusted dosages. Typically, the apolipoprotein formulation is a reconstituted high density lipoprotein formulation comprising ApoA1, one or more lipids such as phosphatidylcholine, sphingomyelin and/or phosphatidylglycerol and, optionally, a detergent such as cholate at a level that does not induce liver toxicity.
    Type: Application
    Filed: November 2, 2012
    Publication date: December 25, 2014
    Inventor: Craig Rayner
  • Publication number: 20140371426
    Abstract: The present invention provides, in one aspect, a method for producing Apolipoprotein in a plant comprising incubating or growing a plant comprising a nucleic acid construct comprising, consisting or consisting essentially of a nucleic acid sequence encoding an Apolipoprotein fusion protein that comprises a fusion protein partner that induces the formation of a protein body in a plant, preferably, wherein the nucleic acid construct is introduced or infiltrated into the plant prior to the incubating or growing step.
    Type: Application
    Filed: December 21, 2011
    Publication date: December 18, 2014
    Applicant: PHILIP MORRIS PRODUCTS S.A.
    Inventors: Karen Oishi, Manuel Peitsch
  • Publication number: 20140348869
    Abstract: The factor H binding activity of meningococcal fHBP can be uncoupled from its bactericidal sensitivity. NMR studies have identified various amino acid residues involved in the fHBP/fH interaction and one or more of these residues is modified in a fHBP to reduce or eliminate its ability to bind to fH.
    Type: Application
    Filed: July 18, 2014
    Publication date: November 27, 2014
    Inventors: Lucia BANCI, Francesca CANTINI, Sara DRAGONETTI, Maria Antonietta GENTILE, Daniele VEGGI, Maria SCARSELLI, Mariagrazia PIZZA
  • Patent number: 8871723
    Abstract: An invention relates to a glycan-modified soluble receptor or binding protein of a cytokine, growth factor, lipoprotein or oxidized lipoprotein, modified to carry a terminal Gal, GlcNAc or GalNAc.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: October 28, 2014
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Menachem Rubinstein, Ariel Werman, Ben Alkahe
  • Publication number: 20140303086
    Abstract: Apolipoprotein M forms a complex with sphingosine-1-phosphate (S1P) and is the carrier of S1P in high density lipoprotein particles and mediates its endothelial protective effect. Increasing the concentration of the apoM/S1P complex by administering it, either alone or in HDL particles, can prevent or treat diseases caused by endothelial cell injury, including inflammatory diseases, sepsis, atherosclerosis and acute lung injury, ischemic heart disease, stroke, vital organ failure after ischemic stress.
    Type: Application
    Filed: May 23, 2012
    Publication date: October 9, 2014
    Inventor: Timothy HLA
  • Publication number: 20140294885
    Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.
    Type: Application
    Filed: April 3, 2014
    Publication date: October 2, 2014
    Applicant: NOVARTIS AG
    Inventors: Maria Beatrice ARICO, Maurizio COMANDUCCI, Cesira GALEOTTI, Vega MASIGNANI, Marzia Monica GIULIANI, Mariagrazia PIZZA
  • Publication number: 20140294757
    Abstract: A method for preserving a polypeptide comprising: (a) providing an aqueous solution of (i) the polypeptide, (ii) one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating the polypeptide.
    Type: Application
    Filed: October 5, 2012
    Publication date: October 2, 2014
    Applicant: Stabilitech Ltd.
    Inventors: Jeffrey Drew, David Thomas Woodward, Stephen Ward
  • Publication number: 20140271700
    Abstract: Described herein are isolated polypeptides each containing one or more receptor-binding sites of toxin A (tcdA) of Clostridium difficile (Cd), nucleic acids encoding the polypeptides, and methods of using the polypeptides and nucleic acids.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: National Health Research Institutes
    Inventors: Pele Choi-Sing Chong, Jui-Hsin Huang, Chih-Hsiang Leng
  • Publication number: 20140234274
    Abstract: The present invention provides methods of achieving directed evolution of viruses by in vivo screening or “panning” to identify viruses comprising scrambled AAV capsids having characteristics of interest, e.g., tropism profile and/or neutralization profile (e.g., ability to evade neutralizing antibodies). The invention also provides scrambled AAV capsids and virus particles comprising the same.
    Type: Application
    Filed: January 17, 2014
    Publication date: August 21, 2014
    Applicant: University of North Carolina at Chapel Hill
    Inventors: Xiao Xiao, Lin Yang
  • Publication number: 20140234942
    Abstract: A solid substrate for the extraction, stabilization, and storage of proteins is provided. The substrate includes: a polysaccharide, such as melezitose under a substantially dry state. The substrate is configured to extract proteins from a sample and stabilize the extracted proteins in a dry format under ambient conditions for a prolonged period of time. Methods for collecting and recovering the proteins stored in the dry solid substrate are also described.
    Type: Application
    Filed: April 25, 2014
    Publication date: August 21, 2014
    Applicant: GENERAL ELECTRIC COMPANY
    Inventors: Ernest William Kovacs, Erik Leeming Kvam, Bing Li, Frank John Mondello
  • Publication number: 20140227322
    Abstract: A method of producing a virus like particle (VLP) in a plant is provided. The method comprises introducing a first nucleic acid into the plant, or portion of the plant. The first nucleic acid comprising a first regulatory region active in the plant operatively linked to a nucleotide sequence encoding a native rabies virus structural protein. The nucleotide sequence may further comprise one or more than one amplification element. Optionally, a second nucleic acid might be introduced into the plant, or portion of the plant. The second nucleic acid comprising a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a matrix protein, for example but not limited to a rabies matrix protein. The plant or portion of the plant is incubated under conditions that permit the expression of the nucleic acids, thereby producing the VLP.
    Type: Application
    Filed: June 13, 2012
    Publication date: August 14, 2014
    Applicant: MEDICAGO INC.
    Inventors: Marc-Andre D'Aoust, Pierre-Olivier Lavoie, Louis-Philippe Vezina, Manon Couture
  • Publication number: 20140227296
    Abstract: The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 14, 2014
    Inventors: Steven A. Porcelli, Maurice Zauderer
  • Publication number: 20140219974
    Abstract: Embodiments of the invention are directed to compositions comprising a peptide sequence, or a nucleic acid encoding the same, wherein the peptide sequence includes a receptor-binding region of apolipoprotein E (apoE), or a sequence variant or fragment thereof, for directing delivery of a given protein or therapeutic across the blood brain barrier. Embodiments of the invention are also directed to methods of using the compositions for treating or preventing a neurological disorder, disease, or symptom in a subject in need thereof.
    Type: Application
    Filed: May 18, 2012
    Publication date: August 7, 2014
    Applicant: Children's Hospital Medical Center
    Inventor: Dao Pan
  • Patent number: 8795685
    Abstract: Described is the use of a mutation of at least one amino acid in the immunosuppressive domain of a HIV or SIV accessory protein, for modulating the immunosuppressive property of the protein.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: August 5, 2014
    Assignees: Institut Gustave Roussy, Centre National de la Recherche Scientifique, Universite Paris Sud XI
    Inventors: Martial Renard, Marianne Mangeney, Thierry Heidmann
  • Publication number: 20140213501
    Abstract: The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.
    Type: Application
    Filed: December 11, 2013
    Publication date: July 31, 2014
    Applicant: Cerenis Therapeutics Holding S.A.
    Inventors: Jean-Louis DASSEUX, Rose ACKERMANN, Daniela Carmen ONICIU
  • Patent number: 8791063
    Abstract: Herein is reported a shortened tetranectin-apolipoprotein A-I fusion protein and a lipid particle comprising the shortened tetranectin-apolipoprotein A-I fusion protein as well as uses thereof.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: July 29, 2014
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Martin Bader, Roberto Falkenstein, Christian Schantz
  • Publication number: 20140206600
    Abstract: The present disclosure provides charged lipoprotein complexes that include as one component a negatively charged phospholipid that is expected to impart the complexes with improved therapeutic properties.
    Type: Application
    Filed: November 20, 2013
    Publication date: July 24, 2014
    Applicant: Cerenis Therapeutics Holding S.A.
    Inventor: Jean-Louis DASSEUX
  • Patent number: 8784926
    Abstract: The present invention relates to methods for the separation of various components from eggs. More particularly, the present invention relates to methods for the separation of proteins and lipids from eggs, including technical eggs (inedible) or edible eggs, yolks or whites, which comprises cross-linking the lipids of eggs with a cross-linking reagent. In an embodiment, the method includes separating the proteins from the cross-linked lipids. In an embodiment, the method includes the separation of various components associated with the cross-linked lipids. The methods disclosed herein allow for the isolation of multiple different components from the egg in an efficient, cost-effective manner without compromising the recovery process of the components or their subsequent utility in various applications or compositions. The compositions and isolated components obtained by the methods of the invention can be used in pharmaceutical, medical, nutritional, cosmetic or health applications.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: July 22, 2014
    Assignee: Biova, L.L.C.
    Inventors: Ronald E. Strohbehn, Jesse I. Figgins
  • Publication number: 20140193846
    Abstract: Novel isoforms of apolipoprotein C-I (apoC-I), namely apolipoprotein C-I1 (apoC-I1) and apolipoprotein C-I1? (apoC-I1?), both of which have a molecular weight of approximately 90 daltons greater than native apolipoprotein C-I (SEQ ID NO:6) and native apolipoprotein C-I? (SEQ ID NO:7), are shown to be both biomarkers for diagnosing atherosclerotic disease as well as risk factors for subjects having increased risk of developing an atherosclerotic disease.
    Type: Application
    Filed: December 23, 2011
    Publication date: July 10, 2014
    Applicants: SCOTT & WHITE HEALTHCARE, THE JOHNS HOPKINS UNIVERSITY, THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Ronald D. Macfarlane, Catherine J. McNeal, Subroto Chatterjee
  • Publication number: 20140171365
    Abstract: Compositions comprising pegylated high density lipoprotein (HDL) particles, methods for producing compositions comprising pegylated HDL particles, and methods of treating various diseases and conditions using pegylated HDL particles are provided.
    Type: Application
    Filed: March 23, 2012
    Publication date: June 19, 2014
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Alan R. Tall, Nan Wang
  • Publication number: 20140162376
    Abstract: The invention provides compositions and methods for assessing the capacity of high density lipoprotein (HDL) to support reverse cholesterol transport in blood by measuring exchange if HDL-specific spin-labeled lipoprotein probes and electron paramagnetic spectroscopy. The invention also provides methods to identify individuals at risk for cardiovascular disease, to monitor the treatment of cardiovascular disease and in the development of therapies to treat cardiovascular disease. The invention also provides methods to identify individuals at risk for Alzheimer's disease, to monitor the treatment of Alzheimer's disease and in the development of therapies to treat Alzheimer's disease.
    Type: Application
    Filed: April 27, 2012
    Publication date: June 12, 2014
    Inventor: Michael N. Oda
  • Publication number: 20140161870
    Abstract: The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.
    Type: Application
    Filed: July 15, 2013
    Publication date: June 12, 2014
    Inventors: David Rabuka, Robert George Edward Holgate, Francis Joseph Carr
  • Publication number: 20140142284
    Abstract: Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins. A complex of all proteins found currently in Plasma, Cryoprecipitate, Fraction III and many newly found proteins now being identified or any substances which are known proteins or unknown proteins which contain good healthy cells and the combination of any of these known or unknown proteins which contain any one of these good healthy cells: Neutrophil, Lymphocyte, Eosinophil, Basophil, and Macrophage, and their potential applications for treating a wide variety of diseases and other physical conditions and disorders, and for maintaining health.
    Type: Application
    Filed: October 17, 2013
    Publication date: May 22, 2014
    Inventor: Kieu Hoang
  • Publication number: 20140127198
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: August 26, 2013
    Publication date: May 8, 2014
    Applicant: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
  • Patent number: 8703496
    Abstract: This invention provides methods of using of the sizes and levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles, the ?641 allele of the promoter of the gene encoding apolipoprotein C-3 (APOC-3), the 405 allele of the gene encoding cholesteryl ester transfer protein (CETP), and plasma levels of insulin-like growth factor-1 (IGF-1), adiponectin, CETP and APOC-3, for determining and increasing an individual's likelihood of longevity and of retaining cognitive function during aging, and for determining and decreasing an individual's likelihood of developing a cardiovascular-, metabolic- or age-related disease.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 22, 2014
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Nir Barzilai, Richard B. Lipton
  • Publication number: 20140094591
    Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A.sub.1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.
    Type: Application
    Filed: December 3, 2013
    Publication date: April 3, 2014
    Applicant: CSL Behring GmbH
    Inventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
  • Publication number: 20140093536
    Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.
    Type: Application
    Filed: July 30, 2013
    Publication date: April 3, 2014
    Inventors: Jiri Pillich, John C. Balcarek
  • Publication number: 20140056820
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.
    Type: Application
    Filed: September 30, 2013
    Publication date: February 27, 2014
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Chang Soo Hong, Tohru Yamada, Arsenio M Fialho
  • Publication number: 20140050733
    Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.
    Type: Application
    Filed: February 7, 2012
    Publication date: February 20, 2014
    Inventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip w. Payne, Robin Barbour
  • Publication number: 20140037672
    Abstract: A fusion protein comprising an antigenic fragment of apoB-100 and a suitable carrier and related compositions methods and systems.
    Type: Application
    Filed: August 5, 2013
    Publication date: February 6, 2014
    Inventors: Jan NILSSON, Goran K. HANSSON, Jan HOLMGREN
  • Publication number: 20140037554
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.
    Type: Application
    Filed: September 9, 2013
    Publication date: February 6, 2014
    Applicant: The Boad of Trustees of the University of Illinois
    Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Arsenio Fialho
  • Publication number: 20140018290
    Abstract: The invention relates to Leptin derivatives, compositions and therapeutic use there-of.
    Type: Application
    Filed: January 24, 2012
    Publication date: January 16, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Janos Tibor Kodra, Kilian Waldemar Conde-Frieboes, Johan Fredrik Paulsson, Kirsten Raun
  • Patent number: 8617615
    Abstract: The present disclosure provides charged lipoprotein complexes that include as one component a negatively charged phospholipid that is expected to impart the complexes with improved therapeutic properties.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: December 31, 2013
    Inventor: Jean-Louis Dasseux
  • Patent number: 8614064
    Abstract: The present invention provides methods and compositions for identifying compounds which inhibit ApoCI and which are useful in the treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for treating subjects suffering from or at risk of developing atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for diagnosing subjects at suffering from or at risk of developing treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: December 24, 2013
    Assignee: The Johns Hopkins University
    Inventors: Subroto Chatterjee, Peter O. Kwiterovich
  • Publication number: 20130331282
    Abstract: Disclosed herein is a marker composition that includes sphingosine 1-phosphate (S1P) protein and that may be used to predict the risk of fracture or osteoporosis; a kit that includes an antibody that specifically binds to the S1P protein and that can be used to predict the risk of fracture or osteoporosis; and a method that can be used to obtain information that allows prediction of the risk of fracture or osteoporosis and includes measurements of S1P protein concentrations by measuring the binding of a S1P-specific antibody to S1P protein. The S1P protein disclosed herein is highly expressed in individuals with fracture, regardless of their bone mineral density. Accordingly, it may be useful as a biomarker of the risk of fracture or osteoporosis.
    Type: Application
    Filed: April 18, 2013
    Publication date: December 12, 2013
    Inventors: Jung Min Koh, Ghi Su Kim, Seung Hun Lee, Beom Jun Kim